

**An observational postmarketing safety registry of patients in the UK, Germany, and Switzerland who have been prescribed Sativex® (THC: CBD, nabiximols) oromucosal spray**

Etges T, Karolia K, Grint T, Taylor A, Lauder H, Daka B, Wright S.

Therapeutics and clinical risk management

2016; 12:1667-1675

**ARTICLE IDENTIFIERS**

DOI: 10.2147/TCRM.S115014

PMID: unavailable

PMCID: not available

**JOURNAL IDENTIFIERS**

LCCN: 2006243617

pISSN: 1176-6336

eISSN: 1178-203X

OCLC ID: 60534739

CONS ID: not available

US National Library of Medicine ID: 101253281

This article was identified from a query of the SafetyLit database.